Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
12 hedge funds and large institutions have $1.72M invested in Zivo Bioscience, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
21% more capital invested
Capital invested by funds: $1.42M → $1.72M (+$305K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.3K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$16.6K |
| 3 |
BC
Bartlett & Co
Cincinnati,
Ohio
|
+$3.33K |
| 4 |
BCWM
Bartlett & Co Wealth Management
Cincinnati,
Ohio
|
+$3.33K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$73K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$66K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$65.3K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $1.25M | -$65.3K | -3,277 | -6% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $359K | +$50.3K | +2,524 | +20% |
|
|
3
Wells Fargo
San Francisco,
California
| $51K | +$16.6K | +833 | +60% |
|
|
VCA
4
Verdence Capital Advisors
Hunt Valley,
Maryland
| $39K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $12K | -$4.78K | -240 | -31% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4K | -$697 | -35 | -17% |
|
|
BC
7
Bartlett & Co
Cincinnati,
Ohio
| $4K | +$3.33K | +167 | New |
|
|
BCWM
8
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $3.88K | +$3.33K | +167 | New |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$73K | -4,247 | Closed |
|
|
XT
11
XTX Topco
George Town,
Cayman Islands
| – | -$66K | -3,829 | Closed |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -313 | Closed |
|
13
Morgan Stanley
New York
| – | -$3.13K | -157 | -88% |
|
|
14
Fidelity Investments
Boston,
Massachusetts
| – | +$139 | +7 | New |
|
ZIVO Hedge Fund Activity: Q1 2022 in Review
12 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q1 2022, worth a combined $1.72M — up 21% from $1.42M a quarter earlier.
Fund positioning in ZIVO was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $50.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $73K sold.
- 12 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1.72M of Zivo Bioscience, Inc. Common Stock stock for Q1 2022, up 21% quarter-over-quarter.
- 3 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of 0 holders.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q1 2022 was Vanguard Group, an estimated $50.3K added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $73K sold.
Based on aggregated 13F filings for Q1 2022.